How We Treat Hemolytic Anemia Due to Pyruvate Kinase Deficiency
Open Access
- 31 August 2024
- journal article
- case report
- Published by MDPI AG in Hematology Reports
- Vol. 16 (3) , 559-567
Abstract
Background: Pyruvate kinase (PK) deficiency is an inherited red blood cell (RBC) enzyme disorder that results in non-immune chronic hemolytic anemia. Characteristic symptoms of PK deficiency include anemia, fatigue, splenomegaly, jaundice, gallstones, thrombosis, and transfusional iron overload. Previously, treatments aimed at symptomatic management with RBC transfusions, phototherapy, folic acid supplementation, splenectomy, and iron chelation therapy when iron overload was documented. Mitapivat, a recently approved medication for treatment of PK-deficiency hemolytic anemia, is an oral allosteric activator of wild-type and mutant RBC PK enzymes. In this paper, we describe three cases of PK-deficiency anemia treated with mitapivat and describe modern management of this rare hemolytic disorder. Methods: A retrospective healthcare database analysis was conducted to extract relevant information. Both quantitative and qualitative methods were integrated to provide a more comprehensive understanding of the cases. Results: Two patients responded well to treatment with mitapivat, noted by an increase in hemoglobin levels, improvements in hemolytic markers, less frequent or no RBC transfusion requirements, and improvements in fatigue. One patient carrying two non-missense mutations of the PKLR gene did not respond to treatment with mitapivat. As variations in patient-specific factors (including genotype) can lead to different clinical manifestations and responses to treatment, we recommend considering both the phenotype (clinical symptoms and signs) and the genotype of the PKLR gene when making therapeutic decisions about starting a patient on mitapivat. Conclusions: While mitapivat addresses the previously unmet needs of most patients with PK deficiency as the first and only disease-modifying medication to receive approval for this condition, not all patients with PK deficiency are amenable to treatment with mitapivat.Keywords
Funding Information
- hematologic malignancy research fund at the Maroone Cancer Center, Cleveland Clinic Florida
This publication has 11 references indexed in Scilit:
- Mitapivat versus Placebo for Pyruvate Kinase DeficiencyNew England Journal of Medicine, 2022
- Comorbidities and complications in adults with pyruvate kinase deficiencyEuropean Journal of Haematology, 2020
- Genotype‐phenotype correlation and molecular heterogeneity in pyruvate kinase deficiencyAmerican Journal of Hematology, 2020
- Long-Term Safety and Efficacy of Mitapivat (AG-348), a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency: The DRIVE PK StudyBlood, 2019
- Safety and Efficacy of Mitapivat in Pyruvate Kinase DeficiencyNew England Journal of Medicine, 2019
- How we manage patients with pyruvate kinase deficiencyBritish Journal of Haematology, 2019
- Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiencyAmerican Journal of Hematology, 2018
- AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiencyBlood, 2017
- Erythrocyte pyruvate kinase deficiency: 2015 status reportAmerican Journal of Hematology, 2015
- A Possible Explanation for Anemia in Patients Treated With Mycophenolic AcidTransplantation, 2011